Search results for "BOC"
showing 10 items of 477 documents
Con li suoi vestimenti asciugare il morto viso della salata acqua, e bagnarlo di molte lagrime: la "Fiammetta" en el "Leànder y Hero" de Roís de Core…
2005
The «Elegia di madonna Fiammetta» has an evident impact of the story of Leandre and Hero, especially in the moments in which the lady suffers while waiting for her lover, who never comes. Fiammetta makes obvious this parallelism on several occasions, and manages to invent an end for the story loaded of pathos. Joan Roís de Corella realises about this relationship between both two works and makes the inverse path: he uses the tone and some narrative elements of the Elegia for writing his Leander and Hero. It is demonstrated that the so contreversial end of Corella’s story is not original of the Valencian, but it also depends on Boccaccio’s text
Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
2019
Key Clinical Message In our case, the use of a low intravenous bolus dose of rFVIIa (recombinant factor VII activated; 15‐20 mcg/kg) was effective and uneventful in controlling late postprocedural PDT bleeding associated with thrombocytopenia that cannot be corrected and after all other treatments failed.
Antibiotic susceptibility of the bacteria causing odontogenic infections
2006
Objetivos: Identificar la flora bacteriana y su susceptibilidad a varios antibióticos utilizados en infecciones odontogénicas de localización periapical y en las pericoronaritis del tercer molar inferior, para poder adaptar convenientemente el tratamiento antibiótico a las exigencias de tales infecciones, y evitar así los efectos secundarios y los sobretratamientos con antibióticos. Material y métodos: Se han seleccionado con unos criterios de inclusión y de exclusión a 64 pacientes que presentaban una infección odontogénica. Se recogieron muestras de las lesiones en condiciones de máxima asepsia, evitando la contaminación por flora saprófita bucal. Las muestras se sembraron en medios de cu…
Paper contagions
2022
Over the weeks of forced self-confinement imposed on us by the pandemic, many of us discovered a sort of thematic library, one which this exceptional and dramatic event seems to have generated by itself: novels, stories, and creative writing more generally that tell of epidemics and quarantines, contagions and pandemics.
The Value of a Complete Blood Count (CBC) for Sepsis Diagnosis and Prognosis.
2021
Sepsis represents an important global health burden due to its high mortality and morbidity. The rapid detection of sepsis is crucial in order to prevent adverse outcomes and reduce mortality. However, the diagnosis of sepsis is still challenging and many efforts have been made to identify reliable biomarkers. Unfortunately, many investigated biomarkers have several limitations that do not support their introduction in clinical practice, such as moderate diagnostic and prognostic accuracy, long turn-around time, and high-costs. Complete blood count represents instead a precious test that provides a wealth of information on individual health status. It can guide clinicians to early-identify …
Association of burning mouth syndrome with xerostomia and medicines
2005
Objetivo: Identificar factores de riesgo para el síndrome de boca ardiente (SBA) a través de estudio de casos y controles. Material y métodos: Se realizó análisis cuantitativo del flujo salival total en reposo y estimulado; se registraron la xerostomía subjetiva, el consumo de medicamentos y los estados psicológicos de ansiedad y depresión en 40 pacientes con SBA y 40 controles. Resultados: El análisis ANOVA mostró diferencias significativas en las medias del número de medicamentos/día, número de medicamentos xerostomizantes/día, xerostomía subjetiva, ansiedad y depresión, entre los grupos estudiados. No se observaron diferencias significativas en las tasas de flujo salival en reposo y esti…
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
2021
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undetected in the individual trials. Methodology: In both trials, patients with an acute episode of aTTP were randomized to receive CPLZ or placebo (PBO) in addition to therapeutic plasma exchange (TPE) and immunosuppression. All randomized patients from both studies were included in the integrated efficacy analyses (CPLZ: n=108; PBO: n=112), and those who received at least 1 dose of the study drug we…
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
2014
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
2020
Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…
Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.
2013
Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…